

IN THE UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF WEST VIRGINIA

<hr/>)	
NOVO NORDISK INC. and NOVO NORDISK A/S))	
<i>Plaintiffs,</i>))	
v.))	Civil Action No. 1:22-cv-00023
MYLAN PHARMACEUTICALS INC.))	
<i>Defendant.</i>))	
<hr/>			

**SUPPLEMENTAL INFORMATION FOR PATENT CASES
INVOLVING AN ABBREVIATED NEW DRUG APPLICATION (ANDA)**

Plaintiffs hereby provide the information below with respect to the deadlines set forth in
21 U.S.C. 355(j):

Date Patentee(s) Received Notice: February 7, 2022

Date of Expiration of Patent: See Below*

Thirty Month Stay Deadline: June 5, 2025**

* U.S. Patent No. 8,114,833 expires on 8/13/2025; U.S. Patent No. 8,684,969 expires on 10/20/2025; U.S. Patent Nos. 9,108,002, 9,616,180, 9,861,757, 10,357,616 and 10,376,652 expire on 1/20/2026; U.S. Patent No. 8,536,122 expires on 3/20/2026; Patent No. RE46,363 expires on 8/3/2026; U.S. Patent No. 9,687,611 expires on 2/27/2027; U.S. Patent Nos. 8,920,383, 9,775,953, 10,220,155, and 11,097,063 expire on 7/17/2026; U.S. Patent No. 9,457,154 expires on 9/27/2027; U.S. Patent No. 9,132,239 expires on 2/1/2032; U.S. Patent No. 8,129,343 expires on 12/5/2031; U.S. Patent No. 10,335,462 expires on 6/21/2033.

** Under 21 C.F.R. Section 314.107(b)(3)(i)(B), the regulatory stay extends until the expiration of 7.5 years from the date of approval of the NDA, rather than 30 months.

DATED: March 18, 2022

Respectfully submitted,

SCHRADER COMPANION DUFF & LAW, PLLC

/s/ James F. Companion

OF COUNSEL:

James F. Companion (#790)

Sandra K. Law, Esq. (#6071)

Jeffrey J. Oelke

401 Main Street

Ryan P. Johnson

Wheeling, WV 26003

Robert E. Counihan

(304) 233-3390

Laura T. Moran

jfc@schraderlaw.com

FENWICK & WEST LLP

skl@schraderlaw.com

902 Broadway, Suite 14

New York, NY 10010-6035

(212) 430-2600

Counsel for Plaintiffs